Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
38,346,880
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
30,637,008
-
Shares change
-
+525,879
-
Total reported value, excl. options
-
$529,755,566
-
Value change
-
+$9,629,460
-
Put/Call ratio
-
10%
-
Number of buys
-
58
-
Number of sells
-
-38
-
Price
-
$17.29
Significant Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q4 2024
120 filings reported holding TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30,637,008 shares
of 38,346,880 outstanding shares and own 80% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (4,865,819 shares), 5AM Venture Management, LLC (4,408,379 shares), MPM ASSET MANAGEMENT LLC (4,381,062 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,903,025 shares), JANUS HENDERSON GROUP PLC (2,080,367 shares), BlackRock, Inc. (1,974,452 shares), VANGUARD GROUP INC (1,464,237 shares), FMR LLC (1,399,916 shares), WELLINGTON MANAGEMENT GROUP LLP (1,031,826 shares), and StepStone Group LP (761,277 shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.